All Comments by Henrik Zetterberg

  1. Diagnostic and Prognostic Utility of the Synaptic Marker Neurogranin in Alzheimer Disease.
  2. Lessons from a failed γ-secretase Alzheimer trial.
  3. GSAP Revisited: Does It Really Play a Role in Processing Aβ?
  4. GSAP Revisited: Does It Really Play a Role in Processing Aβ?
  5. Neuroimaging of Cognitive Dysfunction and Depression in Aging Retired National Football League Players: A Cross-sectional Study.
  6. New AlzRisk Analysis: Brain Injury Promotes Dementia, But Is It AD?
  7. Cochrane Asks for Field’s Input on Draft Reporting Standards
  8. Aβ’s Good Side—Can It Improve Symptoms of Multiple Sclerosis?
  9. Chronic traumatic encephalopathy in blast-exposed military veterans and a blast neurotrauma mouse model.
  10. CSF VILIP-1 predicts rates of cognitive decline in early Alzheimer disease.
  11. Brain Microdialysis Reveals Tau, Synuclein Outside of Cells
  12. Plasma clusterin and the risk of Alzheimer disease.
  13. Identification of low molecular weight pyroglutamate A{beta} oligomers in Alzheimer disease: a novel tool for therapy and diagnosis.
  14. Acute gamma-secretase inhibition of nonhuman primate CNS shifts amyloid precursor protein (APP) metabolism from amyloid-beta production to alternative APP fragments without amyloid-beta rebound.
  15. Sports Concussions, Dementia, and APOE Genotyping: What Can Scientists Tell the Public? What’s Up for Research?